Celgene Corp. (CELG) shares scored a high volume breakout yesterday trading up on over four times its 21-day average volume as its competitor Supergen Inc. (SUPG) had its Dacogen drug nixed at the FDA.  This negative FDA ruling allows Celgene to retain its 71 % market shares in the MDS market with its Revlimid and Vidaza drugs.  The point and figure target for CELG is $ 90.00.